<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04740346</url>
  </required_header>
  <id_info>
    <org_study_id>HC20C0155</org_study_id>
    <nct_id>NCT04740346</nct_id>
  </id_info>
  <brief_title>Survival Rates and Quality of Life According to Follow-up Period After Gastrectomy for Gastric Cancer (STOFOLUP)</brief_title>
  <official_title>A Prospective Multi-center Randomized Clinical Trial to Compare Survival Rates and Quality of Life According to Follow-up Period in Patients Who Underwent Radical Gastrectomy for Advanced Gastric Cancer (STOFOLUP Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea Health Industry Development Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, prospective, randomized controlled study. The aim of this study&#xD;
      is to compare survival rates and to observe quality of life and nutritional status according&#xD;
      to follow-up period in patients who underwent radical gastrectomy for stage 2 or 3 gastric&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis of this study is that the survival rates would be different between the 3&#xD;
      months and 6 months follow-up groups. The investigators expected survival differences of 6%&#xD;
      and the anticipated 3-year overall survival is 83% in the 6 months follow-up group based on&#xD;
      the previous 3 phase clinical trial. On the basis of this hypothesis, the sample size was&#xD;
      calculated as 886 patients.&#xD;
&#xD;
      Patients who were diagnosed as stage 2 or 3 gastric cancer after gastrectomy will be assigned&#xD;
      to 3 months or 6 months follow-up group. The planned examinations including blood test, X-ray&#xD;
      , CT, endoscopy, and nutritional markers will be performed according to the protocol and each&#xD;
      patients will be followed up for 3 years after enrollment.&#xD;
&#xD;
      The primary endpoint is 3 year overall survival and secondary endpoints are other survivals&#xD;
      such as 3-year disease-free survival and gastric cancer specific survival, quality of life,&#xD;
      and nutritional parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year overall survival</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>Death from any cause is defined as an event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-year recurrence-free survival rate</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>Death from any cause and gastric cancer recurrence are an event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year gastric cancer specific survival rate</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>Death from gastric cancer is the only event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year post-recurrence survival rate</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>from recurrence detection date to last follow-up date (or death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary score of KOQUSS-40 questionnaire</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>KOQUSS-40 consists of 8 domains with 40 questions for quality of life and post-gastrectomy symptoms. We will calculate the KOQUSS-40 summary score of each group and compare them between the two groups. The summary score is defined as the mean of eight symptom domains (Indigestion, dysphagia, reflux, dumping syndrome, bowel habit change, constipation, psychological factors, and worry about cancer). The minimum and maximum values are 0 and 100, and higher scores mean a better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary score of EORTC QLQ C30</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>EORTC QLQ C30 consists of 15 domains with 30 questions for quality of life of cancer patients. The 15 domains consist of five functional scales (physical, role, cognitive, emotional, and social functioning), a global QOL scale, three symptom scales (fatigue, nausea and vomiting, and pain), and six single items (appetite loss, diarrhea, dyspnea, constipation, insomnia, financial impact).&#xD;
We will calculate the EORTC QLQ C30 summary score of each group and compare them between the two groups. The summary score is defined as the mean of 13 domains (excluding global QOL scale and financial impact). The minimum and maximum values are 0 and 100, and higher scores mean a better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary score of EORTC QLQ STO22</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>EORTC QLQ STO22 consists of 9 domains with 22 questions for stomach cancer patients' symptoms. The 9 domains consist of five symptom scales (dysphagia, pain, reflux symptom, eating restriction, anxiety), four single items (having a dry mouth, taste, body image, and hair loss).&#xD;
We will calculate the EORTC QLQ STO22 summary score of each group and compare them between the two groups. The summary score is defined as the mean of 9 domains. The minimum and maximum values are 0 and 100, and higher scores mean a better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of body weight (kg)</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>Difference of body weight between preoperative and postoperative 3 year values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of iron deficiency anemia</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>Incidence of iron deficiency anemia for the 3 year follow-up after gastrectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of vitamin B12 deficiency</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>Incidence of vitamin B12 deficiency for the 3 year follow-up after gastrectomy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">886</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Recurrence</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>3 months follow-up</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be follow-up every 3 months after gastrectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 months follow-up</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be follow-up every 6 months after gastrectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Computed tomography, Chest X-ray, and blood test</intervention_name>
    <description>CT will be performed every 3 months after gastrectomy in the 3-months follow-up group. CT will be performed every 6 months after gastrectomy in the 6 months follow-up group.</description>
    <arm_group_label>3 months follow-up</arm_group_label>
    <arm_group_label>6 months follow-up</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 19 years or more&#xD;
&#xD;
          -  Patients who are diagnosed with pathological stage II or III gastric adenocarcinoma&#xD;
             according to the AJCC 8th edition&#xD;
&#xD;
          -  Patients who can understand all information about the trial and decide for themselves&#xD;
             whether to participate in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Vulnerable patients such as pregnant and intellectual disability&#xD;
&#xD;
          -  Patients who cannot undergo CT owing to poor kidney function or severe adverse effects&#xD;
&#xD;
          -  Patients who are already in another study and cannot follow the schedule for this&#xD;
             trial&#xD;
&#xD;
          -  Patients who are diagnosed with a cancer other than gastric cancer within five years&#xD;
             before the gastrectomy&#xD;
&#xD;
          -  Patients being treated for a cancer other than gastric cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keun Won Ryu, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bang Wool Eom, MD PhD</last_name>
    <phone>82-31-920-1689</phone>
    <email>kneeling79@ncc.re.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center, Korea</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keun Won Ryu, PhD</last_name>
      <phone>82-31-920-1628</phone>
      <email>docryu@korea.com</email>
    </contact>
    <contact_backup>
      <last_name>Bang Wool Eom, PhD</last_name>
      <phone>82-31-920-1689</phone>
      <email>kneeling79@ncc.re.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Keun Won Ryu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young-Woo Kim, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hong Man Yoon, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bang Wool Eom, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dongnam Institute of Radiological and Medical Sciences</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Seok Min</last_name>
      <phone>82-10-9567-9488</phone>
      <email>mdoogy@naver.com</email>
    </contact>
    <investigator>
      <last_name>Jae Seok Min</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kyung Won Seo</last_name>
      <phone>82-10-4596-0773</phone>
      <email>hahachristi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Kyung Won Seo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gyeongsang National University Changwon Hospital</name>
      <address>
        <city>Changwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-Ho Jeong</last_name>
      <phone>82-55-214-3771</phone>
      <email>jshgnu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sang-Ho Jeong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Wan Ryu</last_name>
      <phone>82-10-3522-9659</phone>
      <email>koreagsman@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Seung Wan Ryu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Chilgok Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oh Kyoung Kwon</last_name>
      <phone>82-10-4173-3324</phone>
      <email>quack72@naver.com</email>
    </contact>
    <investigator>
      <last_name>Oh Kyoung Kwon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oh Jeong</last_name>
      <phone>82-61-379-7648</phone>
      <email>surgeonjeong@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Oh Jeong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gyeongsang National University Hospital</name>
      <address>
        <city>Jinju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji-Ho Park</last_name>
      <phone>82-10-9335-0510</phone>
      <email>goodgsdr@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ji-Ho Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHA Bundang Medical Center</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Su Mi Kim</last_name>
      <phone>82-10-9933-5261</phone>
      <email>soma21c@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Su Mi Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moon-Won Yoo</last_name>
      <phone>82-10-2965-7588</phone>
      <email>medigang@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Moon-Won Yoo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Min-Hee Ryu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang Hak Yoo, PhD</last_name>
      <phone>82-10-9417-9868</phone>
      <email>chyoo63@naver.com</email>
    </contact>
    <investigator>
      <last_name>Chang Hak Yoo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dong-Hoe Koo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Yeoung An, PhD</last_name>
      <phone>82-10-2717-4610</phone>
      <email>jar319.an@samsung.com</email>
    </contact>
    <investigator>
      <last_name>Ji Yeoung An, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sung Eun Oh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyuk-Joon Lee, PhD</last_name>
      <phone>82-2-2072-1957</phone>
      <email>appe98@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Hyuk-Joon Lee, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han Hong Lee, PhD</last_name>
      <phone>82-10-4326-6039</phone>
      <email>painkiller9@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Han Hong Lee, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kyo Young Song, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ho Seok Seo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chul Hyo Jeon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei Univeristy College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyoung-Il Kim, PhD</last_name>
      <phone>82-10-2556-4986</phone>
      <email>CAIRUS@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Hyoung-Il Kim, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajou University School of Medicine</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hoon Hur, PhD</last_name>
      <phone>82-31-219-4459</phone>
      <email>hhcmc75@naver.com</email>
    </contact>
    <investigator>
      <last_name>Hoon Hur, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Keun Won Ryu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

